Cerevance
Focus: Cerevance is a Boston-based public biotech company focused on CNS small molecules for neurology indications. The company markets DAXXIFY (botulinum toxin type A) at peak lifecycle stage and maintains an early-stage pipeline targeting Parkinson's disease and schizophrenia.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$5M
Open Jobs
0
About Cerevance
AI assessmentNot HiringNo open roles listed right now. Follow Cerevance to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Peak
Approved botulinum toxin franchise operating at peak commercial maturity, anchoring company revenue and supporting neurology platform expansion.
Products & Portfolio (1)
Help build intelligence for Cerevance
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.